ASX Announcement COMPLETION OF HMBD-002 DRUG PRODUCT MANUFACTURE • HMBD-002 has been approved for release and clinical use in accordance with Good Manufacturing Practice (GMP) standards. • HMBD-002 Drug Product to be shipped to Vandebilt Health for use in acute myeloid leukaemia (AML) and...
Completion of HMBD-002 Drug Product Manufacture
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The drug product will be shipped to Vanderbilt Health for use in clinical trials targeting acute myeloid leukaemia and myelodysplastic syndrome. This milestone is crucial for the upcoming investigator-sponsored study, with trial startup activities expected to begin soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Quarterly Activities Report and Appendix 4C
- Photosoft & Novel Immunotherapy Collab Partnership
- PER: Percheron and Invion Explore Cancer Combination Therapy
- Change of Director's Interest Notice
- Notice under S708A
Later from Percheron Therapeutics
- Listing Rule waiver to allow quotation of PERAQ options
- FDA Clearance for Vanderbilt Health Clinical Trial in AML
- Prospectus - Placement options and JLM options
- Update - Proposed issue of securities - PER
- Notification regarding unquoted securities - PER
